Rx Industry Pricing Model Must Change, Former Merck CEO Vagelos Says
Executive Summary
The pharmaceutical industry needs to rethink its approach to pricing or face dire consequences, former Merck CEO Roy Vagelos told the Pharma, Biotech & Device Colloquium in Princeton, N.J. June 9
You may also be interested in...
Levin Calls Takeda/Shire Merger ‘Inspired,’ Says Entire Value Chain Must Address Pricing Issue
Having previously criticized the biopharma industry for squandering the benefits of US tax reform, the former Teva CEO called for more M&A deals that offer a clear strategic rationale, pointing to Takeda/Shire as an example.
Drug Development Needs “Extreme Makeover,” Researcher Topol Says
The pharmaceutical business needs an "extreme makeover," Cleveland Clinic cardiologist Eric Topol, MD, maintained during the 2004 Medical Innovation Summit in Cleveland
Drug Development Needs “Extreme Makeover,” Researcher Topol Says
The pharmaceutical business needs an "extreme makeover," Cleveland Clinic cardiologist Eric Topol, MD, maintained during the 2004 Medical Innovation Summit in Cleveland